Tethys Bioscience (Emeryville, CA) a commercial-stage diagnostics company focused on type II diabetes risk assessment through the measurement of multiple biomarkers, closed a $25M Series D financing. Participants include Capital AG, Wasatch Advisors, Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb